| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56d86159434a525861e451d6868abdff |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 |
| filingDate |
2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fa940b914a5902092a040e8ed31353d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e9cdbdca1516f928372e35781ba080a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6abd0daa019aeb7904f8f44790ebe4c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48dc7ba6b668c2610c149706c85e3a99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab1e3849e5b74b54ff93893dde843f87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec6a9c38876f8983e67f0b9eb7d0acb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ab24491b95b3a633fc76c14c307444b |
| publicationDate |
2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109055318-A |
| titleOfInvention |
Hybridoma cell line A4-6A2 and its procalcitonin monoclonal antibody and application |
| abstract |
The invention provides a hybridoma cell line A4‑6A2, a procalcitonin monoclonal antibody produced by the cell line and an application thereof. The hybridoma cell line A4-6A2 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: C2017143. The procalcitonin monoclonal antibody can be used in immunoassay methods. The present invention also provides a group of paired antibodies, which are composed of antibodies produced by hybridoma cell line A4-6A2 and antibodies produced by hybridoma cell line A4-1B1, and the hybridoma cell line A4-1B1 is preserved in China Typical Culture Collection Center, the deposit number is CCTCC NO: C2017144. The paired antibodies described above can be used in immunoassay methods. The antibody provided by the invention has high specificity, sensitive response and low cost, and is suitable for large-scale application in clinical detection kits. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110747171-A |
| priorityDate |
2018-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |